UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.113

Sortiert nach

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Annals of oncology, 2014-02, Vol.25 (2), p.423-428

2014

Volltextzugriff (PDF)

Comparison of CT volumetric measurement with RECIST response in patients with lung cancer

European journal of radiology, 2016-03, Vol.85 (3), p.524-533

2016

Volltextzugriff (PDF)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Annals of oncology, 2019-05, Vol.30 (5), p.839-844

2019

Volltextzugriff (PDF)

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Annals of oncology, 2018-10, Vol.29 (10), p.2085-2091

2018

Volltextzugriff (PDF)

Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase

Clinical cancer research, 2000-12, Vol.6 (12), p.4885-4892

2000

Volltextzugriff (PDF)

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of oncology, 2015-07, Vol.26 (7), p.1421-1427

2015

Volltextzugriff (PDF)

Proposal for classifying the acute emetogenicity of cancer chemotherapy

Journal of clinical oncology, 1997-01, Vol.15 (1), p.103-109

1997

Volltextzugriff (PDF)

Chemotherapy remains an essential element of personalized care for persons with lung cancers

Annals of oncology, 2016-10, Vol.27 (10), p.1829-1835

2016

Volltextzugriff (PDF)

Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution

Clinical nephrology, 2009-02, Vol.71 (2), p.130

2009

Volltextzugriff (PDF)

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v232-v243

2010

Volltextzugriff (PDF)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Annals of oncology, 2016-07, Vol.27 (7), p.1286-1291

2016

Volltextzugriff (PDF)

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Neuro-oncology (Charlottesville, Va.), 2011-12, Vol.13 (12), p.1364-1369

2011

Volltextzugriff (PDF)

Deciphering radiological stable disease to immune checkpoint inhibitors

Annals of oncology, 2022-08, Vol.33 (8), p.824-835

2022

Volltextzugriff (PDF)

A Comparison of Visual Analogue and Numerical Rating Scale Formats for the Lung Cancer Symptom Scale (LCSS): Does Format Affect Patient Ratings of Symptoms and Quality of Life?

Quality of life research, 2005-04, Vol.14 (3), p.837-847

2005

Volltextzugriff (PDF)

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

Cancer Immunology, Immunotherapy, 2005-10, Vol.54 (10), p.1018-1025

2005

Volltextzugriff (PDF)

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers

Annals of oncology, 2016-01, Vol.27 (1), p.154-159

2016

Volltextzugriff (PDF)

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Annals of oncology, 2017-02, Vol.28 (2), p.278-284

2017

Volltextzugriff (PDF)

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069

Journal of clinical oncology, 1997-02, Vol.15 (2), p.790-795

1997

Volltextzugriff (PDF)

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

The Lancet (British edition), 2010-04, Vol.375 (9722), p.1267-1277

2010

Volltextzugriff (PDF)

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach

The Journal of thoracic and cardiovascular surgery, 2000-03, Vol.119 (3), p.429-439

2000

Volltextzugriff (PDF)

Long Survival of Patients with Small Cell Lung Cancer after Adjuvant Treatment with the Anti-Idiotypic Antibody BEC2 Plus Bacillus Calmette-Guérin

Clinical cancer research, 1999-06, Vol.5 (6), p.1319-1323

1999

Volltextzugriff (PDF)

Development of Inhalational Agents for Oncologic Use

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1839-1847

2001

Volltextzugriff (PDF)

Variations in Lung Cancer Risk Among Smokers

JNCI : Journal of the National Cancer Institute, 2003-03, Vol.95 (6), p.470-478

2003

Volltextzugriff (PDF)

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

Annals of oncology, 2000-02, Vol.11 (2), p.227-228

2000

Volltextzugriff (PDF)

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

Journal of clinical oncology, 1994-06, Vol.12 (6), p.1232-1237

1994

Volltextzugriff (PDF)

1 – 25 von 2.113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.951)
Mit Volltextzugriff
(1.872)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(2.107)
Japanisch
(326)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(198)
Journal Of Thoracic Oncology
(52)
Clinical Cancer Research
(38)
The American Journal Of Clinical Nutrition
(32)
Cancer
(31)
Plos One
(29)
The Faseb Journal
(29)
Scientific Reports
(26)
The Journal Of Nutrition
(24)
Neurology
(22)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Comparison of CT volumetric measurement with RECIST response in patients with lung cancer

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Proposal for classifying the acute emetogenicity of cancer chemotherapy

Chemotherapy remains an essential element of personalized care for persons with lung cancers

Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Deciphering radiological stable disease to immune checkpoint inhibitors

A Comparison of Visual Analogue and Numerical Rating Scale Formats for the Lung Cancer Symptom Scale (LCSS): Does Format Affect Patient Ratings of Symptoms and Quality of Life?

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach

Long Survival of Patients with Small Cell Lung Cancer after Adjuvant Treatment with the Anti-Idiotypic Antibody BEC2 Plus Bacillus Calmette-Guérin

Development of Inhalational Agents for Oncologic Use

Variations in Lung Cancer Risk Among Smokers

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

Suchergebnisse filtern